Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gallium Ga-68 Gozetotide

FDA-approved product (solution, intravenous), marketed as Gallium Ga 68 Gozetotide, Gozellix, Illuccix and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gallium Ga-68 Gozetotide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neuroimaging measurement

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gallium Ga-68 Gozetotide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gallium Ga-68 Gozetotide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach

    NCT05420727 · start 2023-02-08

    Registered record
    Registry ID
    NCT05420727
    Conditions
    Soft Tissue Sarcoma
    Interventions
    Ga-68-PSMA-11 PET/CT; Lu-177-ITG-PSMA-1
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-02-08
    Completion
    2024-04-30
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma
    InterventionGa-68-PSMA-11 PET/CT; Lu-177-ITG-PSMA-1
    PhasePhase 1
    Registry statusCompleted

  • Dual-Tracer Theranostic PET

    NCT05680675 · start 2022-12-08

    Registered record
    Registry ID
    NCT05680675
    Conditions
    Neuroendocrine Tumors; Prostate Cancer
    Interventions
    Single-Tracer FDG PET/CT Exam; Single-Tracer Cu64-DOTATATE PET/CT Exam; Single-Tracer Ga68-DOTATATE PET/CT Exam; Single-Tracer PSMA PET/CT Exam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-12-08
    Completion
    2024-06-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors; Prostate Cancer
    InterventionSingle-Tracer FDG PET/CT Exam; Single-Tracer Cu64-DOTATATE PET/CT Exam; Single-Tracer Ga68-DOTATATE PET/CT Exam; Single-Tracer PSMA PET/CT Exam
    PhaseNot applicable
    Registry statusCompleted

  • PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

    NCT04243941 · start 2022-11-29

    Registered record
    Registry ID
    NCT04243941
    Conditions
    Prostate Cancer
    Interventions
    68Ga-HBED-CC-PSMA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-11-29
    Completion
    2024-02-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention68Ga-HBED-CC-PSMA
    PhasePhase 2
    Registry statusWithdrawn

  • Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma

    NCT06600399 · start 2022-10-01

    Registered record
    Registry ID
    NCT06600399
    Conditions
    Glioblastoma
    Interventions
    glioblastoma
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2024-02-29
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma
    Interventionglioblastoma
    PhaseNot recorded
    Registry statusCompleted

  • A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

    NCT05562791 · start 2022-09-28

    Registered record
    Registry ID
    NCT05562791
    Conditions
    Bladder Cancer
    Interventions
    [68Ga]PSMA; PET/CT imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-09-28
    Completion
    2027-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer
    Intervention[68Ga]PSMA; PET/CT imaging
    PhasePhase 1
    Registry statusRecruiting

  • EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

    NCT05150236 · start 2022-04-29

    Registered record
    Registry ID
    NCT05150236
    Conditions
    Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Prostate Cancer; Neoplasms by Site; Neoplasms; Prostatic Disease
    Interventions
    177Lu-PSMA-617; Ipilimumab; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-04-29
    Completion
    2024-12
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Prostate Cancer +3 more
    Intervention177Lu-PSMA-617; Ipilimumab; Nivolumab
    PhasePhase 2
    Registry statusUnknown

  • Clinical Application of the Prototype J-PET Device

    NCT06211803 · start 2022-03-11

    Registered record
    Registry ID
    NCT06211803
    Conditions
    Neurodegenerative Diseases; Brain Neoplasms; Neuroendocrine Tumors
    Interventions
    Positron-Emission Tomography Imaging
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-03-11
    Completion
    2022-03-22
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurodegenerative Diseases; Brain Neoplasms; Neuroendocrine Tumors
    InterventionPositron-Emission Tomography Imaging
    PhaseNot recorded
    Registry statusCompleted

  • Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617

    NCT05170555 · start 2021-12-01

    Registered record
    Registry ID
    NCT05170555
    Conditions
    Renal Cell Carcinoma
    Interventions
    68Ga-PSMA; 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2023-07-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    Intervention68Ga-PSMA; 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
    PhaseNot applicable
    Registry statusUnknown

  • A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer

    NCT05073653 · start 2021-10-11

    Registered record
    Registry ID
    NCT05073653
    Conditions
    Prostate Cancer
    Interventions
    68Ga-PSMA PET/CT; 68Ga-GRP PET/CT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-10-11
    Completion
    2022-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention68Ga-PSMA PET/CT; 68Ga-GRP PET/CT
    PhaseNot applicable
    Registry statusUnknown

  • Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms

    NCT06835244 · start 2021-09-17

    Registered record
    Registry ID
    NCT06835244
    Conditions
    PSMA Positive Tumors or Tumor Tissues; Cancer
    Interventions
    68Ga-PSMA-11
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2021-09-17
    Completion
    2031-06
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPSMA Positive Tumors or Tumor Tissues; Cancer
    Intervention68Ga-PSMA-11
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma

    NCT05006326 · start 2021-08-16

    Registered record
    Registry ID
    NCT05006326
    Conditions
    Malignant Neoplasm
    Interventions
    68Ga-PSMA; PET/MR; PET/CT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-16
    Completion
    2023-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm
    Intervention68Ga-PSMA; PET/MR; PET/CT
    PhaseNot applicable
    Registry statusUnknown

  • 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)

    NCT04726033 · start 2021-08-04

    Registered record
    Registry ID
    NCT04726033
    Conditions
    Metastatic Prostate Cancer
    Interventions
    64Cu-DOTA-TLX592
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2021-08-04
    Completion
    2024-01-29
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    Intervention64Cu-DOTA-TLX592
    PhaseEarly phase 1
    Registry statusCompleted

  • Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

    NCT04867603 · start 2021-06-29

    Registered record
    Registry ID
    NCT04867603
    Conditions
    Prostate Cancer
    Interventions
    [Ga-68]PSMA; PET/CT imaging
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-06-29
    Completion
    2022-10-03
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention[Ga-68]PSMA; PET/CT imaging
    PhaseNot recorded
    Registry statusCompleted

  • Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).

    NCT04745871 · start 2021-05-20

    Registered record
    Registry ID
    NCT04745871
    Conditions
    Prostate Cancer
    Interventions
    PSMA PET/CT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2021-05-20
    Completion
    2025-11-21
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPSMA PET/CT
    PhaseNot applicable
    Registry statusTerminated

  • [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer

    NCT04484701 · start 2021-02-01

    Registered record
    Registry ID
    NCT04484701
    Conditions
    Prostatic Neoplasm; Prostatic Cancer
    Interventions
    68Ga-PSMA-11
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-02-01
    Completion
    2028-09
    Enrolment
    1,574

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasm; Prostatic Cancer
    Intervention68Ga-PSMA-11
    PhaseNot recorded
    Registry statusActive not recruiting